In this issue of the JCI, Chen et al. present an AAV gene therapy for CLN7 that shows marked benefit in a mouse model of CLN7 Batten disease, paving the way for a phase I trial. The gene discussed is MFSD8; the disease is juvenile neuronal ceroid lipofuscinosis.